GlassScriptPhysician profile
Kathleen Hesterman
NPI 1528301041
$7,268.66
in general payments reported to CMS, 2019-2025
26 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $433 · 2021: $1,021 · 2022: $1,261 · 2023: $1,961 · 2024: $1,357 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,470 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $878 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,470.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $877.50 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,998.39 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $792.70 | 2022-2025 | |
| Janssen Biotech, INC. | $784.72 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Allergan, INC. | $681.53 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $536.04 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $435.48 | 2020-2025 | |
| Ucb, INC. | $381.80 | 2020-2024 | Bimzelx, Cimzia |
| Leo Pharma INC. | $237.28 | 2020-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $190.59 | 2023-2025 | Sotyktu |
| Pfizer INC. | $172.75 | 2019-2023 | |
| Lilly USA, LLC | $165.85 | 2020-2023 | Taltz |
| Amgen INC. | $146.75 | 2020-2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $106.43 | 2021-2024 | Siliq, Duobrii, Targretin |
| Sun Pharmaceutical Industries INC. | $96.32 | 2021-2025 | |
| Galderma Laboratories, L.P. | $79.11 | 2021-2025 | Aklief, Nemluvio, Epsolay |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $68.02 | 2023-2024 | Vtama |
| Epi Health, LLC | $64.85 | 2021-2022 | |
| Revance Therapeutics, INC. | $56.32 | 2025 | Daxxify |
| Strata Skin Sciences, INC. | $50.48 | 2023-2024 | Xtrac |
| Arcutis Biotherapeutics, INC. | $24.84 | 2025 | Zoryve |
| Biofrontera INC. | $24.76 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Vyne Pharmaceuticals INC. | $20.70 | 2021 | |
| Incyte Corporation | $20.33 | 2024 | Opzelura |
| Mayne Pharma Commercial LLC | $19.66 | 2025 | |
| Verrica Pharmaceuticals INC. | $15.12 | 2023 | Ycanth |
| Solta Medical, A Division of Bausch Health US, LLC | $14.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Hesterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.